Vascular calcification burden of Chinese patients with chronic kidney disease: methodology of a cohort study

BMC Nephrology

the China Dialysis Calcification Study (CDCS) Group¹  Zhi-Hong Liu¹ 

[1] National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, 305 East Zhong Shan Road, Nanjing 210016, China

关键词: Dialysis;    End-stage renal disease;    Vascular calcification;    Mineral metabolism;    Chronic kidney disease;   

Others  :  1222295
DOI  :  10.1186/s12882-015-0132-3

 received in 2015-04-19, accepted in 2015-07-28,  发布年份 2015

【 摘 要 】

Background

Vascular calcification is a common complication associated with chronic kidney disease and the major cause of cardiovascular disease in patients with end-stage renal disease. The vascular calcification risk burden is still unknown in China. This study aims to investigate the prevalence of vascular calcification and assess the predictive value of vascular calcification in patients with stage 5 chronic kidney disease on dialysis in China.

Methods/Design

This is a national, multicenter, non-interventional, prospective cohort study planning to recruit 1520 patients with end-stage renal disease receiving hemodialysis or peritoneal dialysis for at least 6 months in 24 dialysis centers in China. All the patients provided written informed consents before participating in this study. It will include a baseline visit and 24 months follow-up period with 4 other visits at 6-month intervals. Vascular calcification images will be obtained to determine the prevalence of vascular calcification, coronary artery calcification, abdominal aortic calcification and cardiac valve calcification. Association between vascular calcification and all-cause and cardiovascular disease mortality and non-fatal cardiovascular events will be assessed. Disease management, as assessed by serum level of calcium, phosphorus and intact parathyroid hormone and its impact on vascular calcification, will also be surveyed.

Discussion

The new results gained from this study will supplement limited current available data and provide better clinical decisions in Chinese patients with chronic kidney disease on dialysis.

【 授权许可】

   
2015 Liu et al.

【 参考文献 】

• [1]Zhang L, Wang F, Wang L, Wang W, Liu B, Liu J et al.. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012; 379:815-22.
• [2]Hallan SI, Coresh J, Astor BC, Asberg A, Powe NR, Romundstad S et al.. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol. 2006; 17:2275-84.
• [3]Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P et al.. Prevalence of chronic kidney disease in the United States. JAMA. 2007; 298:2038-47.
• [4]Wang F, Zhang L, Wang H. Awareness of CKD in China: a national cross-sectional survey. Am J Kidney Dis. 2014; 63:1068-70.
• [5]Yue X, Binyan S. Kun Zhao. Epidemiology features of end-stage renal disease and the application, cost and payment of dialysis care in China. Chin J Health Pol. 2011; 4:29-33.
• [6]Karohl C, D’Marco Gascón L, Raggi P. Noninvasive imaging for assessment of calcification in chronic kidney disease. Nat Rev Nephrol. 2011; 7:567-77.
• [7]Matsuoka M, Iseki K, Tamashiro M, Fujimoto N, Higa N, Touma T et al.. Impact of high coronary artery calcification score (CACS) on survival in patients on chronic hemodialysis. Clin Exp Nephrol. 2004; 8:54-8.
• [8]Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002; 62:245-52.
• [9]Sigrist M, Bungay P, Taal MW, McIntyre CW. Vascular calcification and cardiovascular function in chronic kidney disease. Nephrol Dial Transplant. 2006; 21:707-14.
• [10]Garland JS, Holden RM, Groome PA, Lam M, Nolan RL, Morton AR et al.. Prevalence and association of coronary artery calcification in patients with stages 3 to 5 CKD without cardiovascular disease. Am J Kidney Dis. 2008; 52:849-58.
• [11]Adeney KL, Siscovick DS, Ix JH, Seliger SL, Shlipak MG, Jenny NS et al.. Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol. 2009; 20:381-7.
• [12]Russo D, Palmiero G, De Blasio AP, Balletta MM, Andreucci VE. Coronary artery calcification in patients with CRF not undergoing dialysis. Am J Kidney Dis. 2004; 44:1024-30.
• [13]Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004; 15:2208-18.
• [14]Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ et al.. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA. 2011; 305:1119-27.
• [15]Kendrick J, Chonchol M. The role of phosphorus in the development and progression of vascular calcification. Am J Kidney Dis. 2011; 58:826-34.
• [16]Lilien MR, Groothoff JW. Cardiovascular disease in children with CKD or ESRD. Nat Rev Nephrol. 2009; 5:229-35.
• [17]O’Neill WC, Lomashvili KA. Recent progress in the treatment of vascular calcification. Kidney Int. 2010; 78:1232-9.
• [18]Kong X, Zhang L, Zhang L, Chen N, Gu Y, Yu X et al.. Mineral and bone disorder in Chinese dialysis patients: a multicenter study. BMC Nephrol. 2012; 13:116. BioMed Central Full Text
• [19]Disease K. Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013; 3:1-150.
• [20]K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39:S1-S266.
• [21]KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009; 113:S1-S130.
• [22]Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990; 15:827-32.
• [23]Kauppila LI, Polak JF, Cupples LA, Hannan MT, Kiel DP, Wilson PW. New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis. 1997; 132:245-50.
• [24]Cheng X, Nayyar S, Wang M, Li X, Sun Y, Huang W et al.. Mortality rates among prevalent hemodialysis patients in Beijing: a comparison with USRDS data. Nephrol Dial Transplant. 2013; 28:724-32.
• [25]Tripepi G, Jager KJ, Dekker FW, Wanner C, Zoccali C. Bias in clinical research. Kidney Int. 2008; 73:148-53.